Enjoy complimentary customisation on priority with our Enterprise License!
The global HIV drugs market size is estimated to grow by USD 10,477.51 million at a CAGR of 5.46% between 2022 and 2027.
The increasingly higher detection of HIV AIDS worldwide is positively impacting the market growth. As access improves, HIV management is more effective and can result in a growing population who experience longer lifespans and require long-term treatment. This results in a greater number of HIV patients which will increase the demand for HIV drugs globally. In addressing these new challenges, advanced antiretroviral therapies and other treatment innovations will play a critical role. These new trends and advances shall result in the growth of the global HIV drug market in the foreseeable future.
Technavio has segmented the market into distribution channel, therapy, and geography.
It also includes an in-depth analysis of drivers, trends, and challenges.
To learn more about this report, Request Free Sample
Offline segment
The market share growth by the offline segment will be significant during the forecast period. Offline distribution of HIV drugs by dispensing medications through pharmacies, hospitals, clinics, and healthcare facilities shall a vital role in the global market for HIV drugs. This is due to limited internet penetration or connectivity or a preference for in-person interactions with doctors, nurses, and other healthcare providers in certain regions of the world.
Get a glance at the market contribution of various segments View a PDF Sample
The offline segment was valued at USD 24,925.65 million in 2017. Certain people have a degree of trust and familiarity with physical healthcare options and providers, hence, contributing to the growth of the offline segment of the HIV drugs market during the forecast period.
The combination HIV medicines segment, also called ART, involves the administration of several drugs from different classes, such as NRTIs, integrase inhibitors, and fusion inhibitors to manage and treat HIV at different stages of its life cycle. This reduces the possibility of replication and increases the viral load, creating more potent and effective regimens that can inhibit the growth of the virus. They have turned a former deadly condition into a more manageable condition that can be avoided from escalation to AIDS. Hence, the Combination HIV medicines segment of the HIV drugs market is likely to witness growth during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 49% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Due to innovations and growth in medical research, advanced healthcare infrastructure, and increased awareness about HIV/AIDS, the North American region is the largest regional market for HIV drugs. Having a robust pharmaceutical industry, greater levels of government and private organizations interactions and collaborations have expanded the market growth. Newer innovations such as the usage of pre-exposure prophylaxis medication, the introduction of long-acting therapies, and gene-editing techniques like CRISPR/Cas9 hold great potential for the development of curative treatments in the long run. Improved access in underdeveloped regions, which are more vulnerable, is advancing HIV treatment and prevention strategies. Hence the above, Therefore, the above-mentioned changes are improving the growth of the regional HIV drugs market during the forecast period.
The COVID-19 pandemic with the closure of regional healthcare facilities and suspension of diagnostic services as well as procedures negatively impacted the HIV drugs market. However, large-scale vaccination and the resumption of pharmaceutical manufacturing and logistics after the easing of lockdown restrictions reduced R&D constraints. Hence, the demand for HIV drugs resumed from Q1 2021 with regular diagnostic services and treatments in North America operating. Hence, the North American HIV drug market is expected to witness growth during the forecast period.
Buy Now Full Report and Discover More
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market vendors, including:
AbbVie Inc. - The company offers HIV drugs such as Kaletra and Aluvia.
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
Expanding access to HIV treatment is a key trend in the market. Increased government, international organizations, and NGO involvement have resulted in greater resource allocation to target the global HIV epidemic. Initiatives like the President Emergency Plan for AIDS Relief (PEPFAR) are a good example. This has resulted in improved infrastructure, better healthcare systems, and increased availability of HIV drugs globally. There is also the development of easier treatment regimens with simple administration and fewer resources, for instance into a single pill, which makes adherence simpler.
Additionally, the production of generic versions of HIV drugs that are more affordable makes access greater in developing and underdeveloped parts of the world. All these factors also contribute to the prevention of mother-to-child transmission (PMTCT) of the virus by providing antiretroviral drugs to pregnant women living with HIV. However, factors such as funding gaps, stigma, and healthcare infrastructure limitations are barriers that prevent universal access to treatment and hinder the market growth during the forecast period.
The increasing drug resistance among individuals is challenging market growth. Human immunodeficiency virus (HIV) has a high mutation rate which enables it to develop resistance to antiretroviral drugs used in treatment. If individuals do not follow the prescribed treatment regimen and are irregular, then the virus can mutate and develop resistance to the drugs. This can cause failure in antiretroviral drug treatment of HIV, causing the disease to progress further, potentially limiting the number of treatment options.
Additionally, drug-resistant strains of HIV can even be transmitted to others, posing far more deadly health risks to the public at large. This will require further healthcare investment and laboratory spending to identify the drug-resistant strains and treat the mutated version of the virus. Hence, increasing drug resistance is hindering the market growth during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global HIV Drugs Market Customer Landscape
The HIV drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
HIV Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
158 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.46% |
Market growth 2023-2027 |
USD 10,477.51 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
4.55 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 49% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Aspen Pharmacare Holdings Ltd, Aurobindo Pharma Ltd., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cipla Ltd., Emcure Pharmaceuticals Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Hetero Labs Ltd., Johnson and Johnson Services Inc., Lupin Ltd., Macleods Pharmaceuticals Ltd., Merck and Co. Inc., Strides Pharma Science Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris Inc., and Cadila Pharmaceuticals Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Therapy
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.